
Jan 22 (Reuters) - Corcept Therapeutics Inc CORT.O:
OVERALL SURVIVAL PRIMARY ENDPOINT MET IN CORCEPT’S PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER
CORCEPT THERAPEUTICS INC - DATA SHOW 35% REDUCTION IN RISK OF DEATH
CORCEPT THERAPEUTICS INC - PHASE 3 ROSELLA TRIAL MEETS OVERALL SURVIVAL ENDPOINT